smi's 9th annual imaging in cancer drug development event
DESCRIPTION
TRANSCRIPT
Anthony GiamisHead of RadiochemistryAbbott
Peter EggletonMedical Director OncologyMerck
Werner ScheuerResearch Leader Preclinical Imaging;Pharma Research and Early DevelopmentRoche
Francois LasaillyIn-vivo Imaging SpecialistCancer Research UK
Albert WindhorstHead of Radiopharmaceutical ChemistryVU University
Erik ArstadSenior Lecturer in RadiochemistryUCL
Prash KrishnaDirector – Oncology Clinical DevelopmentEisai
Yanping LuoGroup Leader, Translational ImagingAbbott
Kevin BrindleProfessor of Biomedical MagneticResonanceCambridge University
Laura KennyClinical Senior Lecturer/Consultant inMedical OncologyImperial College
Janos Kriston-ViziGroup Leader of Bioinformatics Image CoreMedical Research Council
Teng Jin OngGlobal Clinical Leader in OncologyBayer
KEY SPEAKERS INCLUDE:
KEY TOPICS FOR 2013:• Latest developments in fluorescence and bioluminescence for drug
monitoring in xenografts• Novel target identification and lead discovery in preclinical biomarkers and
radiochemistry• Strengths and limitations of whole body optical imaging with X-ray micro CT
and multiphoton intravital microscopy• Overcoming challenges in nuclear tracers for multiscale imaging in oncology• Current application of PET/SPET modalities and a review of PFS
(progression-free survival) • Practical tools for business expansion in the current economic climate
SMi present their 9th annual conference on...
Imaging in CancerDrug DevelopmentClinical Application and Innovation13th and 14th March 2013, Copthorne Tara Hotel, London, UK
To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737, email [email protected]
or visit www.smi-online.co.uk/ts07.asp to register online
REGISTER BY 7TH DECEMBER AND RECEIVE A £300 DISCOUNTREGISTER BY 18TH JANUARY AND RECEIVE A £200 DISCOUNT
PLUS INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPTuesday 12th March 2013, Copthorne Tara, London, UK
Development of radiopharmaceuticals for PET Imaging in Oncology Workshop Leader:
Albert Windhorst, Head of Radiopharmaceutical Chemistry, VU University13.00 – 17.00
Sponsored by
To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737 email [email protected] or visit www.smi-online.co.uk/ts07.asp to register online
Supported by
Imaging in Cancer Drug Development 2013Day One | Wednesday 13th March 2013 www.smi-online.co.uk/ts07.asp
08.30 Registration and Coffee
09.00 Chairman's Opening Remarks Peter Eggleton, Medical Director Oncology, Merck
09.10 Application of in vivo and ex vivo imaging in the drug developmentprocess: monitoring primary tumor growth, metastasis andangiogenesis• Application of fluorescence and bioluminescence for drug
monitoring in xenografts • Monitoring primary tumor growth, metastasis and angiogenesis• Simultaneous measurement of pharmacodynamics and
pharmacokinetics• Future aspects (Cerenkov and hybrid systems)Werner Scheuer, Principle Optical Imaging, Roche
09.50 Novel advances in molecular imaging using the PhotonIMAGEROPTIMA system• Novel targets• Compare and contrast analogues• Challenges faced with novel targets• Future developmentsNicolas Carvou, Application Scientist, Biospace Lab
10.30 Morning Refreshments
PRE-CLINICAL & CLINICAL IMAGING
11.00 Non-invasive imaging of pre-clinical models for basic translationalresearch• Whole body optical imaging (bioluminescence and NIR fluorescence),
X-ray micro CT and multiphoton intravital microscopy• Strengths and limitations• Ongoing developments Francois Lasailly, In-vivo Imaging Specialist, Cancer Research UK
11.40 Overcoming chemical challenges in radiotracer development • Synthesis of dual optical and nuclear tracers for multiscale imaging • Preparation of functional nanoparticles for imaging with SPECT
and MRI• One-pot ‘click-labelling’ of chemically labile precursors • 18F aromatic labelling of ‘drug-like’ tracersErik Arstad, Senior Lecturer in Radiochemistry, UCL
12.20 Networking Lunch
CURRENT ROLE OF IMAGING MODALITIES
13.40 Watching tumours gasp and die with MRI• Early detection of treatment response - why and how• Imaging tumour metabolism with hyperpolarised 13C-labelled cell
substrates• Detecting drug response• Detecting tumour cell death• Imaging the tumour microenvironmentKevin Brindle, Professor of Biomedical Magnetic Resonance,Cambridge University
14.20 Current role of PET/CT in cancer imaging – hybrid imaging improvesthe assessment of bone metastasis• The skeleton is a common site for metastases and newer treatment
are under investigation• Bone metastases are usually considered “non-measurable” • Hybrid imaging provides new insight in the assessment of bonemetastases Yong Du, Consultant in Nuclear Medicine and PET/CT, Royal MarsdenHospital
15.00 Afternoon Tea
QUANTITIVE STUDIES & CHANGING PERSPECTIVES
15.30 Quantitative in vivo imaging of disease and response to therapy• Promise and peril of in vivo imaging• FRAP of eCadherin to study EMT• Sub-cellular targeting of Rho• Spatial and temporal dynamics of Src response Kurt Anderson, Oncology Team Leader, The Beatson Institute forCancer Research
16.10 Independent Radiological Committe (IRC) review for PFS - revisited• IRC and its role in oncology drug development• IRC versus Inv led Reviews• Changing Perspectives Prash Krishna, Director – Oncology, Clinical Development, Eisai
16.50 Chairman’s closing remarks
17.00 Close of day one
SPONSORSHIP AND EXHIBITIONOPPORTUNITIES
SMi offer sponsorship, exhibition, advertisingand branding packages, uniquely tailored to
complement your company’s marketingstrategy. Prime networking opportunities
exist to entertain, enhance and expand yourclient base within the context of an
independent discussion specific to yourindustry. Should you wish to join the
increasing number of companies benefitingfrom sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: [email protected]
Sponsored by
Biospace Lab’s range of instruments is dedicated to smallanimal preclinical imaging.
Biospace Lab has developed a comprehensive portfolio ofex vivo, in vivo and now in actio imaging solutions; whichare used by almost every major pharmaceutical companyand prestigious academic research institutes worldwide.www.biospacelab.com
Day Two | Thursday 14th March 2013
• Imaging andTranslational Medicine
• Molecular Imaging• Cancer Research• Oncology • Pre-clinical Imaging• Clinical Imaging
• PET Research• Biomarkers• Target Discovery• Pharmacokinetics/
Pharmacodynamics• Drug Discovery &
Design
• Computer-Aided DrugDesign
• ComputationalChemistry
• Structure andInformatics
• Molecular Interaction
• Medical Imaging• Clinical Pharmacology• Biophysics• Screening• Clinical Development• Structural Biology
Who should attend this conference:You should attend this event if you are a Director, Area Head, Chief Executive, Chief ScientificOfficer, Vice President, Heads, Principal Scientist or Manager within the Pharmaceutical orHealthcare industry with responsibilities in the following areas:
Want to know how you can get involved? Interested in
promoting your pharmaceuticalservices to this market?
Contact Kellee Halliburton, SMi Marketing
on +44 (0) 207 827 6194, or email [email protected]
8.30 Re-registration and Coffee
09.00 Chairman's Opening RemarksAnthony Giamis, Head of Radiochemistry, Abbott
IMAGING BIOMARKERS IN CANCER DRUG DEVELOPMENT
09.10 PET/SPECT imaging biomarker development• Target identification and lead finding• Radiochemistry aspects• Preclinical evaluation• Translation towards clinicAlbert Windhorst, Head of Radiopharmaceutical Chemistry, VU University
09.50 The importance of efficient early detection and diagnosis • Observing tumor location(s), tumor-associated neoangiogenesis,
suppression of antitumor immunity and visualising expression• Activity of specific molecules and biological processes that influence
tumor behaviour and response to therapy• Impact on cancer detection, metastases classification, individualized
treatment, and drug development• Bioluminescence and photoacoustic imaging applications Teng Jin Ong, Global Clinical Leader in Oncology, Bayer
10.30 Biomarkers as predictors of therapeutic efficacy• Image-guided therapeutic delivery - development of novel cancer
imaging probes and biomarkers for screening, detection, diagnosis • Utilization of biomarkers for effective patient enrolment and
proficient exchange of treatment paradigms – financial savings in thepharmaceutical industry
• Role of imaging biomarkers in distinguishing metastases – efficientprognosis
• Biomarkers and individualised medicineLaura Kenny, Clinical Senior Lecturer/Consultant in Medical Oncology,Imperial College
11.00 Morning Refreshments
IMPROVING SUCCESS OF IMAGING MODALITIES
11.30 Molecular imaging innovation: PET/SPECT imaging in translationalscience• Choosing a Target or Mechanism• Preparation of Radiotracer• Imaging Translation• Outcome and AssessmentsAnthony Giamis, Head of Radiochemistry, Abbott Laboratories
12.10 Improving medical imaging diagnoses• High quality display and graphics for improved diagnostic abilities
and patient treatment• Explore advancements in diagnoses solutions• Developments in software platforms for imaging in cancer drug
discovery• Innovative multi-display technology – increase number of reviews
per dayYanping Luo, Group Leader, Translational Imaging, Abbott
12.50 Networking Lunch
14.20 Imaging modalities in drug discovery: high-content screening of akinase inhibitor small molecule library to identify autophagy regulators• Imaging modalities incorporating kinase inhibitors• Identifying autophagy regulators• Challenges faced in HTS of kinase inhibitors• Future developmentsJanos Kriston-Vizi, Group Leader of Bioinformatics Image Core, Medical Research Council
15.10 Afternoon Tea
FUTURE OF IMAGING IN CANCER DRUG DEVELOPMENT
15.50 Outmanagement for imaging experts in cancer drug development • Practical tools for survival and growth during a period of
retrenchment• Expansion of medical imaging products in the market• Managing practical issues associated with oncology imaging• Standardization and development of proficiency in the fieldPeter Eggleton, Medical Director Oncology, Merck
16.30 The pricing and reimbursement environment• Key changes to payers willingness to pay • The cost containment programmes in key markets• How to ‘prove’ ValueBrian Lovatt, CEO, Vision Healthcare
17.10 Chairman’s closing remarks
17.20 Close of day two
www.smi-online.co.uk/ts07.asp
To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737 email [email protected] or visit www.smi-online.co.uk/ts07.asp to register online
In association withVU University
Workshop Leader: Albert Windhorst, Head ofRadiopharmaceutical Chemistry, VU University
Overview of workshop:This workshop will be a unique interactive sessionwhere attendees can explore the development ofradiopharmaceuticals for PET Imaging in Oncology,alongside emerging ideas and case studies that can beapplied to their own roles and environments. Led by theexpertise and experience of Albert Windhorst, of VUUniversity, the workshop will explore the treatment ofpatients early in their disease process and facilitate theunderstanding of unmet needs in cancer drugdevelopment and oncology imaging.
Overview of workshop:• Discover the benefits of developing
radiopharmaceuticals for PET Imaging in oncologyresearch
• Address and overcome the key challengesassociated with developing radiopharmaceuticalsfor PET Imaging
• Evaluate past experiences and case studies andbenefit from lessons learnt
• Engage in an interactive session with a uniqueplatform for discussion
Workshop Agenda:13.00 Registration and coffee
13.30 Welcome & Introductions
13.40 Route from conceptual idea to humanapplication of a PET radiopharmaceutical• Identify biological targets for imaging• Identify lead compounds for
radiopharmaceutical development
14.15 Small molecule PET tracer development andmonoclonal antibody PET tracers• Nuclides and radiochemistry • Considerations for development
15.15 Afternoon Break
15.30 Translation from preclinical research toclinical research• Animal experiments and typical studies• GMP production and legislation
16.30 Discussion Session
17.00 Close of Workshop
About the workshop hostDr Windhorst currently holds a position as associateprofessor in radiopharmaceutical chemistry at the VUUniversity Medical Center, where he heads theradiopharmaceutical chemistry section of thedepartment of Nuclear Medicine & PET Research. Hismain research interest is in the development andproduction of 11C and 18F radiolabeled compounds forclinical PET imaging, both research as for routineapplications.
He is member of the board of the NKRV, EANM DrugDevelopment committee, president elect of the SRS,chairman of the 19th International Symposium onRadiopharmaceutical Chemistry, member of thescientific advisory board of the Journal LabeledCompounds and Radiopharmaceuticals and of CurrentRadiopharmaceuticals.
About VU UniversityResearch at VU University Amsterdam covers a widerange of fields that often cut across disciplinaryboundaries. Within the Radionuclide Centre (RNC)scientific research with radioactive material isperformed. The RNC has facilities for all kinds ofchemical, biological and medical research withRadionuclides at Type-2-level.
HALF-DAY PRE-CONFERENCE WORKSHOPTuesday 12th March 2013
13.00 – 17.00Copthorne Tara Hotel, London, UK
Development ofradiopharmaceuticals for PET
Imaging in Oncology
SMI PHARMACEUTICALFORWARD PLANNER 2013
JANUARY
Biomarkers Summit16 – 17 January 2013, London
Social Media in the Pharma Industry23 – 24 January 2013, London
Quality by Design23 – 24 January 2013, London
Pre-Filled Syringes28 – 29 January 2013, London
Pharmaceutical Microbiology30 – 31 January 2013, London
FEBRUARY
Parallel Trade6 – 7 February 2013, London
Advances and Progress in Drug Design18 – 19 February 2013, London
Lyophilisation - Freeze Drying inPharmaceuticals
and Biopharmaceuticals25 – 26 February 2013, London
MARCH
Superbugs & Superdrugs - A Focus onAntibacterials
4 – 5 March 2013, London
Imaging in Cancer Drug Development13 – 14 March 2013, London
Controlled Release18 – 19 March 2013, London
Paediatric Clinical Trials20 – 21 March 2013, London
APRIL
Adaptive Designs8 – 9 April 2013, London
Asthma & COPD15 – 16 April 2013, London
Pharmaceutical Portfolio & LifecycleManagement
17 – 18 April 2013, London
MAY
Generics, Supergenerics& Patent Strategies
13 – 14 May 2013, London
Pain Therapeutics20 – 21 May 2013, London
ADC Summit20 – 21 May 2013, London
Clinical Trial Logistics22 – 23 May 2013, London
JUNE
RNAi & Nanotechnology5 – 6 June 2013, London
IMAGING IN CANCER DRUG DEVELOPMENT Conference: Wednesday 13th and Thursday 14th March 2013, Copthorne Tara Hotel, London, UK Workshop: Tuesday 12th March 2013, London
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 20 7827 6737PHONE on +44 (0) 20 7827 6736
ONLINE at www.smi-online.co.uk/ts07.aspPOST your booking form to: Cem Tuna, SMi Group Ltd, 2nd Floor South,Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
If you have NOT received registration confirmation within 48 hours of registering, please call +44 (0) 20 7827 6736
Payment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then credit carddetails will be requested and payment taken before entry to the event. Bookings within 7 days ofevent require payment on booking. Access to the Document Portal will not be given until paymenthas been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send asubstitute, then we will refund/credit 50% of the due fee less a £50 administration charge,providing that cancellation is made in writing and received at least 28 days prior to the start of theevent. Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unable toattend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about otherproducts and services. Unless you tick here □ we may also share your data with third partiesoffering complementary products or services. If you have any queries or want to update any of thedata that we hold then please contact our Database Manager [email protected] visit our website www.smi-online.co.uk/updates quoting the URN as detailed above youraddress on the attached letter.
Unique Reference Number
Our Reference LVP-060 ts
Terms and Conditions of Booking
DELEGATE DETAILSPlease complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment must be made to SMi Group Ltd, and received before the event, by one of thefollowing methods quoting reference P-060 and the delegate’s name. Bookings made within7 days of the event require payment on booking, methods of payment are below. Pleaseindicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATIONI cannot attend but would like to purchase access to the following DocumentPortal/paper copy documentation Price Total□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR
□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: [email protected] or fax +44 (0) 870 9090 712
□ Book by 7th December to receive a £300 off the conference price□ Book by 18th January to receive a £200 off the conference price
EARLY BIRDDISCOUNT
VATVAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on DocumentPortal and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: ______________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop only £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotionalliterature to all conference attendees £999.00 + VAT £1198.80
GROUP DISCOUNTS AVAILABLE
The conference fee includes refreshments, lunch, conference papers and access
to the Document Portal containing all of the presentations.